Limited vs Diffuse Scleroderma: Prognosis Differences

Limited and diffuse scleroderma are two subtypes of the same underlying disease, but they follow very different paths. Diffuse scleroderma tends to progress fast in the first few years, with widespread skin thickening and a high risk of serious internal organ damage. Limited scleroderma moves more slowly, often staying confined to the hands and face for years, but it carries its own long-term risks — particularly pulmonary arterial hypertension, which can appear decades after diagnosis. Neither subtype is mild, but understanding the differences helps you and your doctor watch for the right complications at the right times.

This explainer draws on peer-reviewed research from five scleroderma specialists listed in the Convene directory. Laura Hummers, M.D., co-directs the Johns Hopkins Scleroderma Center and co-authored the landmark EUSTAR mortality study, as well as research on pulmonary hypertension survival in scleroderma. Dinesh Khanna, M.D., at Michigan Medicine co-led the 2013 ACR/EULAR classification criteria and the 2016 EULAR treatment guidelines. John Varga, MD, Chief of Rheumatology at the University of Michigan, published foundational work on the fibrosis mechanisms that drive both subtypes. Kristin Highland, M.D., at Cleveland Clinic led key research on treating the lung complications common in diffuse disease. Flavia Castelino, M.D., at Massachusetts General Hospital led the largest prospective US cohort study of early diffuse scleroderma.

What separates limited from diffuse scleroderma

Systemic sclerosis — the formal name for scleroderma — is classified by how much skin is involved. The 2013 ACR/EULAR classification criteria, co-authored by Khanna and published in Arthritis & Rheumatism, updated the diagnostic framework that physicians use to confirm the diagnosis and distinguish its forms [1].

In diffuse cutaneous systemic sclerosis (dcSSc), skin thickening extends above the elbows and knees or involves the trunk. You might notice tightness and hardening spreading up the forearms, across the chest, or onto the abdomen. This widespread skin involvement usually appears within the first one to three years of disease and signals that organ fibrosis — in the lungs, heart, kidneys, and digestive tract — is likely to follow.

In limited cutaneous systemic sclerosis (lcSSc), thickened skin stays below the elbows and knees, and typically affects just the fingers, hands, and face. Many people with limited disease had Raynaud's phenomenon (color changes in the fingers triggered by cold or stress) for years before any skin changes appeared. A 2017 review in The Lancet co-authored by Khanna describes this slower disease course and the distinct organ complication patterns that emerge over time [2].

The two subtypes also differ in their autoantibody profiles, which matter for prognosis:

• Anti-centromere antibodies appear in roughly half of people with limited SSc and predict a slower disease course with higher pulmonary hypertension risk later in life.
• Anti-topoisomerase I (anti-Scl-70) antibodies are more common in diffuse SSc and correlate with interstitial lung disease.
• Anti-RNA polymerase III antibodies appear almost exclusively in diffuse SSc, associate with rapid skin progression and kidney crisis, and — in work published by Hummers and colleagues — also correlate with a striking temporal overlap between scleroderma onset and cancer diagnosis [12].

At a glance

Organ complications: what to watch for in each subtype

Lung complications

Interstitial lung disease (ILD) — scarring of the lung tissue — develops in a large share of people with diffuse SSc. A 2020 review in The Lancet Respiratory Medicine co-authored by Highland describes SSc-ILD as one of the leading causes of death in this disease, particularly in diffuse cutaneous disease where lung fibrosis can be extensive [17]. Screening with pulmonary function tests and high-resolution CT is done routinely in diffuse SSc precisely because ILD can be present before you notice shortness of breath.

In limited SSc, ILD occurs less often and tends to be less severe, though it still develops in a meaningful number of patients and should be monitored.

Pulmonary arterial hypertension (PAH) — elevated blood pressure inside the arteries that feed the lungs — is a different complication and follows an almost opposite pattern: it is more common in limited SSc than diffuse SSc. Work from the Johns Hopkins group, including research co-authored by Hummers and published in Arthritis & Rheumatism, confirmed that scleroderma-related PAH carries worse survival than idiopathic PAH, even when blood pressure measurements look similar [2]. A separate Johns Hopkins cohort study, also involving Hummers, showed that when SSc-related pulmonary hypertension is complicated by ILD, the prognosis is particularly poor — and that early diagnosis and treatment are associated with better outcomes [6].

Heart and kidney complications

Diffuse SSc poses greater risks to the heart and kidneys early in disease. The myocardium (heart muscle) can become fibrotic, causing arrhythmias or heart failure. Scleroderma renal crisis — a sudden rise in blood pressure and kidney failure — is rare but serious, occurring mainly in diffuse SSc and especially in patients with anti-RNA polymerase III antibodies.

A prospective US cohort of 301 patients with early diffuse SSc, published in Arthritis Research & Therapy with Castelino as a co-author, found that 20 patients (6.6%) died over a median follow-up of just over two years. Cardiac involvement was the leading cause, accounting for one-third of those deaths [10].

Gastrointestinal complications

Both subtypes can develop gut dysmotility — slowed or disordered movement through the esophagus, stomach, and intestines. Symptoms range from reflux and swallowing difficulties to bloating, constipation, and malabsorption. This is not specific to either subtype but becomes particularly challenging in long-standing disease of either form.

What the EUSTAR mortality data show

The most comprehensive picture of how scleroderma kills patients comes from the EUSTAR database, analyzed in a 2010 study co-authored by Hummers and published in the Annals of the Rheumatic Diseases. The study captured cause of death for 234 of 284 deaths among 5,860 SSc patients [4].

Among deaths attributed to SSc itself (55% of total), pulmonary fibrosis accounted for 35%, pulmonary arterial hypertension for 26%, and cardiac causes for another 26%. Among deaths not directly attributed to SSc (41% of total), infections (33%), malignancies (31%), and cardiovascular events (29%) dominated. Proteinuria was the strongest independent predictor of death, followed by echocardiographic PAH and pulmonary restriction.

This breakdown reinforces what clinicians observe in practice: diffuse SSc patients face the highest early mortality because they are more likely to develop severe ILD, cardiac fibrosis, and renal crisis in the first decade. Limited SSc patients often survive longer but remain at risk of PAH, which can emerge at any point in the disease course.

Survival numbers

A Johns Hopkins study led by the pulmonary hypertension and scleroderma group, involving Hummers and published in the American Journal of Respiratory and Critical Care Medicine, followed 76 SSc patients with confirmed PAH over a median 36 months [7]. Survival at one year was 85%, at three years 67%, and at five years just 36%. Right ventricular dysfunction and impaired kidney function were the strongest independent predictors of death. These numbers reflect patients who had already developed PAH — a reminder of why early screening matters.

The first few years in diffuse SSc

Diffuse SSc is most dangerous early. Skin thickening typically peaks in the first two to three years, and internal organ damage accumulates fastest during this period. A prospective US cohort study with Castelino as co-author tracked 301 patients with early diffuse SSc from 2012 to 2020 [10]. At baseline, patients had been ill for a median of 1.2 years. Despite immunosuppressive therapy in 63% of participants, 21% experienced significant worsening of skin fibrosis and 23% showed meaningful lung function decline within two years. Six percent died within the study period, most within three years.

This is one reason rheumatologists watch diffuse SSc patients closely in the early years: the window for intervention is real, and many of the treatments available today are aimed at slowing rather than reversing damage.

How treatments differ by subtype

The 2016 update to EULAR treatment recommendations for systemic sclerosis, co-authored by Khanna and published in the Annals of the Rheumatic Diseases, outlines organ-specific therapy for both subtypes [5]. The approach differs by what complications are present or anticipated.

For diffuse SSc with ILD, mycophenolate mofetil and cyclophosphamide have evidence for slowing lung function decline. Nintedanib, an antifibrotic drug, became the first targeted therapy approved specifically for SSc-ILD after the SENSCIS trial showed it reduced the rate of lung function decline — work that Highland contributed to and that was published in the New England Journal of Medicine in 2019 [8]. The ATS clinical practice guideline on SSc-ILD treatment, also co-authored by Highland and published in 2023, recommends nintedanib for patients with progressive ILD alongside immunosuppression [9].

For scleroderma-related PAH, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs are used — the same drug classes used for idiopathic PAH, though patients with scleroderma-related PAH tend to respond less well.

For skin disease in early diffuse SSc, no treatment has consistently reversed fibrosis. Methotrexate and mycophenolate are used to slow skin progression. A phase II trial led by Castelino testing abatacept (a T-cell costimulation blocker) in early diffuse SSc found the drug well-tolerated but did not show significant improvement in skin score as the primary endpoint, though some secondary biological markers suggested activity [11]. Research in this space continues.

Questions to ask your rheumatologist

• Which subtype do I have, and what autoantibodies came back on my blood tests?
• Given my subtype, which organs are most at risk, and how often should we screen them?
• Do I need pulmonary function tests and a high-resolution CT scan now, or at a scheduled interval?
• What is my lung artery pressure, and should I be screened annually for PAH?
• If I have early diffuse disease, am I a candidate for immunosuppressive therapy to slow ILD progression?
• At what point would you consider adding an antifibrotic drug like nintedanib?
• Are there any clinical trials I should know about for my disease subtype?

The bottom line

Limited and diffuse scleroderma are not the same disease in terms of what they do to the body or when. Diffuse SSc is aggressive early, with rapid skin and organ involvement in the first few years and the highest mortality from ILD and cardiac complications. Limited SSc moves slowly but carries long-term risks — pulmonary arterial hypertension in particular — that can appear years or decades after diagnosis. Your autoantibody profile helps predict which complications to watch for. Early, specialist-led monitoring and organ-specific treatment are what separate people who do well from those who do not.